Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H1 2014
LONDON, June 12, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H1 2014
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H1 2014
Summary
Global Markets Direct's, 'Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H1 2014', provides an overview of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Skin And Skin Structure Infections (SSSI) Caused By Bacteria
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Introduction 7
Global Markets Direct Report Coverage 7
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Overview 8
Therapeutics Development 9
Pipeline Products for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Overview 9
Pipeline Products for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Comparative Analysis 10
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Therapeutics under Development by Companies 11
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Products under Development by Companies 16
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Companies Involved in Therapeutics Development 17
GlaxoSmithKline plc 17
Melinta Therapeutics, Inc 18
Paratek Pharmaceuticals, Inc. 19
Debiopharm International S.A. 20
MerLion Pharmaceuticals Pte Ltd 21
Nabriva Therapeutics AG 22
Cempra, Inc. 23
Cellceutix Corporation 24
Tetraphase Pharmaceuticals Inc. 25
Durata Therapeutics, Inc. 26
Furiex Pharmaceuticals, Inc. 27
Microbion Corporation 28
Dong-A Socio Holdings Co Ltd 29
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
dalbavancin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
tedizolid phosphate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
omadacycline tosylate - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
delafloxacin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GSK-1322322 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AFN-1252 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
brilacidin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
BC-3781 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
fusidic acid - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
avarofloxacin hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
eravacycline - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
GSK-2140944 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
BC-7013 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Bismuth ethanedithiol - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
AFN-1252 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
DBAF-101 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecules to Inhibit 50S RNA for Infections - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
finafloxacin - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Recent Pipeline Updates 74
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Dormant Projects 109
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Product Development Milestones 110
Featured News & Press Releases 110
May 05, 2014: Melinta Therapeutics Phase 3 Study Of I.V. And Oral Delafloxacin Has Begun Enrolling Patients With Acute Bacterial Skin And Skin Structure Infections 110
May 02, 2014: Durata Therapeutics to Present Six Dalbavancin Posters at the 24th Annual ECCMID Meeting 110
Apr 30, 2014: Cubist to Present New Pipeline Data Of Tedizolid Phosphate At 2014 European Congress of Clinical Microbiology and Infectious Diseases 112
Apr 24, 2014: Durata Therapeutics Initiates Enrollment in a Phase 3b Study of Dalvance in a 1500 mg Single Dose 112
Apr 01, 2014: Cellceutix Comments on Positive FDA Advisory Vote for Dalbavancin and Tedizolid 113
Mar 31, 2014: Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI 113
Mar 31, 2014: FDA Advisory Committee Unanimously Recommends Approval of Dalvance for the Treatment of Acute Bacterial Skin and Skin Structure Infections 114
Feb 19, 2014: FDA Accepts Filing of the Medicines Company's New Drug Application for Intravenous Antibiotic Oritavancin With Priority Review 114
Feb 03, 2014: Cellceutix Files With FDA for Phase 2b Clinical Trial of Novel Antibiotic Brilacidin; Enrollment of Patients Expected to Start Mid-February 115
Dec 30, 2013: Cubist Announces FDA Acceptance of Tedizolid New Drug Application with Priority Review 115
Appendix 117
Methodology 117
Coverage 117
Secondary Research 117
Primary Research 117
Expert Panel Validation 117
Contact Us 118
Disclaimer 118
List of Tables
Number of Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, H1 2014 9
Number of Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by GlaxoSmithKline plc, H1 2014 17
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Melinta Therapeutics, Inc, H1 2014 18
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Paratek Pharmaceuticals, Inc., H1 2014 19
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Debiopharm International S.A., H1 2014 20
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2014 21
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Nabriva Therapeutics AG, H1 2014 22
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Cempra, Inc., H1 2014 23
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Cellceutix Corporation, H1 2014 24
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2014 25
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Durata Therapeutics, Inc., H1 2014 26
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Furiex Pharmaceuticals, Inc., H1 2014 27
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Microbion Corporation, H1 2014 28
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 29
Assessment by Monotherapy Products, H1 2014 30
Number of Products by Stage and Target, H1 2014 33
Number of Products by Stage and Mechanism of Action, H1 2014 36
Number of Products by Stage and Route of Administration, H1 2014 38
Number of Products by Stage and Molecule Type, H1 2014 40
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics - Recent Pipeline Updates, H1 2014 74
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Dormant Projects, H1 2014 109
List of Figures
Number of Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, H1 2014 9
Number of Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 30
Number of Products by Top 10 Target, H1 2014 31
Number of Products by Stage and Top 10 Target, H1 2014 32
Number of Products by Top 10 Mechanism of Action, H1 2014 34
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 35
Number of Products by Top 10 Route of Administration, H1 2014 37
Number of Products by Stage and Top 10 Route of Administration, H1 2014 38
Number of Products by Top 10 Molecule Type, H1 2014 39
Number of Products by Stage and Top 10 Molecule Type, H1 2014 40
Read the full report:
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H1 2014
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article